Skip to content

Medical emergency? What to do

New hepatitis drug may be more effective

3-RXPublished March 10, 20062 min read

Key points

  • Entecavir, a new drug designed to battle frequently fatal hepatitis B, is more effective than a rival drug, according to a pair of research studies financed by the drug's manufacturer Bristol-Myers Squibb Co.
  • "Entecavir seems to be an outstanding agent for treating chronic hepatitis B," because of its effectiveness and the low rate at which the hepatitis B virus becomes resistant to the drug, Dr.
  • About 1.5 million Americans carry hepatitis B, which is usually spread by contaminated needles or sexual contact.
  • Hepatitis B virus dropped to undetectable levels in 67 percent of the people in the entecavir group, compared with 36 percent of the lamivudine recipients.

Entecavir, a new drug designed to battle frequently fatal hepatitis B, is more effective than a rival drug, according to a pair of research studies financed by the drug's manufacturer Bristol-Myers Squibb Co.

The two studies on long-term liver disease, published in this week's issue of The New England Journal of Medicine, found that entecavir, also known as Baraclude, does a better job than GlaxoSmithKline's drug, Epivir (lamivudine).

"Entecavir seems to be an outstanding agent for treating chronic hepatitis B," because of its effectiveness and the low rate at which the hepatitis B virus becomes resistant to the drug, Dr. Jay Hoofnagle of the National Institute of Diabetes and Digestive and Kidney Diseases wrote in a Journal editorial.

The two drugs are among five approved in the United States to treat hepatitis B infection, which can destroy the liver and lead to liver cancer. A vaccine that prevents hepatitis B is also available, and is routinely given to newborns in Taiwan and China, where the illness is common.

About 1.5 million Americans carry hepatitis B, which is usually spread by contaminated needles or sexual contact.

In a new study of the form of chronic hepatitis known as HBeAg-positive, a team led by Ting-Tsung Chang of the National Cheng Kung University Medical College in Taiwan found that 72 percent of the 314 patients treated with entecavir showed improvement after 48 weeks of treatment. Among the patients who were treated with lamivudine, only 62 percent of the 314 patients improved in the same time period.

Hepatitis B virus dropped to undetectable levels in 67 percent of the people in the entecavir group, compared with 36 percent of the lamivudine recipients.

A second study of 583 HBeAg-negative patients, conducted by many of the same researchers, showed similar results.

In the United States, a month's supply of 0.5 milligram tablets of entecavir costs about $650, four times the cost of lamivudine.

Hoofnagle warned that although the drugs work well, treatment can still be complicated because it's not clear who should be treated, what agent (or combination of agents) to use, how long to treat and the best way to monitor patients.

In addition, the virus can develop resistance to one of the drugs. For example, after four years of taking lamivudine, 70 to 80 percent of patients become resistant to it.

"Perhaps the most promising aspect of entecavir therapy has been the low rate of antiviral resistance," Hoofnagle said.

And if people stop taking anti-hepatitis drugs, the disease tends to return with renewed vigor, which can lead to death. Once treatment with oral antiviral agents has begun, it is difficult to stop," he said.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.